Boundless Bio, Inc.
Clinical trials sponsored by Boundless Bio, Inc., explained in plain language.
-
New cancer drug BBI-355 trial halted early – what we know
Disease control Stopped earlyThis early-phase trial tested a new oral drug called BBI-355, alone or with other targeted therapies, in people with advanced solid tumors that had extra DNA (oncogene amplifications). The study aimed to find the safest dose and check for side effects. It was terminated early, so…
Phase 1 • Sponsor: Boundless Bio, Inc. • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New pill shows promise in early trial for Hard-to-Treat breast cancer
Disease control Stopped earlyThis early-stage study tests a new oral drug, BBI-940, in people with advanced or metastatic breast cancer that has not responded to standard treatments. The drug works by breaking down a protein that helps cancer cells grow. The study aims to find the safest dose and check for s…
Phase 1 • Sponsor: Boundless Bio, Inc. • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Experimental cancer drug BBI-825 tested in early trial
Disease control Stopped earlyThis early-phase trial tested an oral drug called BBI-825 in 19 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and check for side effects. The study was terminated early, so results are limited.
Phase 1 • Sponsor: Boundless Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC